Plenary Lectures (PL)
|
Mary L. (Nora) Disis, MD |
CV
|
University of Washington, USA
Vaccines for cancer prevention and treatment
|
|
|
Tyler E. Jacks, PhD |
CV
|
Koch Institute for Integrative Cancer Research at MIT, USA
Dissecting tumor evolution
|
|
Educational Sessions (ES)
ES1. Cancer proteogenomic atlas
6/17(Thu) 15:20-17:00
cv
Michael A. Gillette
Broad Institute of MIT and Harvard, USA
cv
Daehee Hwang
Seoul National University College of Natural Sciences
cv
Hui Zhang
Johns Hopkins University, USA
cv
Hyun Seok Kim
Yonsei University College of Medicine
ES2. Organ-based hypofractionated radiotherapy
6/17(Thu) 15:20-17:00
cv
Jun Won Kim
Gangnam Severance Hospital, Yonsei University College of Medicine
cv
Eui Kyu Chie
Seoul National University College of Medicine
cv
Jae Myoung Noh
Sungkyunkwan University School of Medicine
cv
Kyubo Kim
Ewha Womans University College of Medicine
ES3. Overcoming resistance to targeted and immune therapies
6/18(Fri) 15:10-16:50
cv
Jeeyun Lee
Sungkyunkwan University School of Medicine
cv
Tae-Yong Kim
Seoul National University College of Medicine
cv
In-Ho Kim
The Catholic University of Korea College of Medicine
cv
Jee Suk Chang
Yonsei University College of Medicine
ES4. Artificial intelligence in cancer imaging and digital pathology
6/18(Fri) 15:10-16:50
cv
Hwiyoung Kim
Yonsei University College of Medicine
cv
Ji Eun Park
Asan Medical Center
cv
Yosep Chong
The Catholic University of Korea College of Medicine
cv
Jeong Mo Bae
Seoul National University Hospital
Young Investigator Symposium (YIS)
YIS1. Young Investigator Symposium [KOR]
6/17(Thu) 15:20- 17:00
cv
Shin Kim
Keimyung University School of Medicine
cv
Galam Leem
Yonsei University College of Medicine
cv
Chaeuk Chung
Chungnam National University College of Medicine
SP01. Cancer epigenetics and its clinical applications
6/17(Thu) 10:30-12:10
cv
Céline Vallot
Institut Curie, France
cv
Anders Lindroth
National Cancer Center, Korea
cv
Toshikazu Ushijima
National Cancer Center Research Institute, Japan
cv
Jung Kyoon Choi
Korea Advanced Institute of Science and Technology (KAIST)
SP02. Non-invasive monitoring of minimal residual disease
6/17(Thu) 10:30-12:10
cv
Duhee Bang
Yonsei University College of Science
cv
Seung-Tae Lee
Yonsei University College of Medicine
cv
Wonshik Han
Seoul National University College of Medicine
cv
Eun-Hae Cho
Green Cross Genome
SP03. Multidisciplinary treatment for bone metastases
6/17(Thu) 10:30-12:10
cv
Naresh Kumar
National University Hospital, Singapore
cv
Su Ssan Kim
University of Ulsan College of Medicine
cv
Kazuo Okamoto
The University of Tokyo, Japan
cv
Jin-Hee Ahn
University of Ulsan College of Medicine
SP04. DNA damage response (DDR) treatment:
Diagnostic approach and treatment resistance
6/17(Thu) 13:30-15:10
cv
Seock-Ah Im
Seoul National University College of Medicine
cv
Kyung Hae Jung
University of Ulsan College of Medicine
cv
Robert Samstein
Icahn School of Medicine at Mount Sinai, USA
cv
Timothy A. Yap
MD Anderson Cancer Center, USA
SP05. Lymph node exploration in cancer surgery
6/17(Thu) 13:30-15:10
cv
Seong Yong Park
Yonsei University College of Medicine
cv
Jun Woo Lee
Ewha Womans University Mokdong Hospital
cv
Keun Won Ryu
National Cancer Center
cv
Sandra L. Wong
Dartmouth-Hitchcock Medical Center, USA
SP06. Precision medicine and immunotherapy for pediatric cancer
6/17(Thu) 13:30-15:10
cv
Donald Williams Parsons
Baylor College of Medicine, Texas Children's Cancer and Hematology Centers, USA
cv
Jeong A Park
Memorial Sloan Kettering Cancer Center, USA
cv
Jae-Kyung Won
Seoul National University Hospital
cv
Hyoung Jin Kang
Seoul National University College of Medicine
SP07. Era of next generation¡¯s cancer immunotherapy
6/18(Fri) 10:30-12:10
cv
Dario Campana
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
cv
Sangyong Jon
Korea Advanced Institute of Science and Technology (KAIST)
cv
Seung-Woo Lee
Pohang University of Science and Technology (POSTECH)
cv
Chae Ok Yun
Hanyang University College of Engineering
SP08. Surgical innovation in cancer
6/18(Fri) 10:30-12:10
cv
Takeaki Ishizawa
University of Tokyo, Japan
cv
Joon Seong Park
Gangnam Severance Hospital, Yonsei University College of Medicine
cv
Ji Won Park
Seoul National University Hospital
cv
Chang Wook Jeong
Seoul National University Hospital
SP09. Proton therapy and FLASH irradiation
6/18(Fri) 10:30-12:10
cv
Dongryul Oh
Sungkyunkwan University School of Medicine
cv
Won Il Jang
Korea Cancer Center Hospital
cv
Young Kyung Lim
National Cancer Center
cv
Jong-ki Kim
Daegu Catholic University School of Medicine
SP10. COVID-19 in cancer patients
6/18(Fri) 13:20-15:00
cv
Pyoeng Gyun Choe
Seoul National University College of Medicine
cv
Vivian E. Strong
Memorial Sloan Kettering Cancer Center, USA
cv
Yeon Hee Park
Sungkyunkwan University School of Medicine
SP11. The evolving landscape for endometrial cancer treatment
6/18(Fri) 13:20-15:00
cv
Hyojin Kim
Seoul National University Bundang Hospital
cv
Mi-Kyung Kim
Ewha Womans University Mokdong Hospital
cv
Yong Wha Moon
CHA University School of Medicine
cv
Jinhwa Hong
Korea University College of Medicine
SP12. ±¹°¡¾Ïµ¥ÀÌÅÍ Á¤º¸ °øÀ¯
6/18(Fri) 15:10-16:50
cv
Youngsik Bang
Ministry of Health and Welfare
cv
Kui Son Choi
National Cancer Center, Graduate School of Cancer Science and Policy
cv
Dong Wook Kim
National Health Insurance Service
cv
Kyong Hwa Park
Korea University College of Medicine
Satellite Symposia (SS)
Satellite Symposium 1 (AstraZeneca)
6/17(Thu) 08:30-08:50
|
Tae Min Kim |
CV
|
Seoul National University College of Medicine
Transforming therapeutic strategy from advanced to early stage EGFR-mutation positive NSCLC
|
|
Satellite Symposium 2 (ONO/BMS)
6/17(Thu) 08:50-09:10
|
Sun Min Lim |
CV
|
Yonsei University College of Medicine
Recent update of CheckMate 9LA and CheckMate 227 pivotal trials in 1L NSCLC
|
|
Satellite Symposium 3 (Yuhan)
6/17(Thu) 09:10-09:30
|
Byoung Chul Cho |
CV
|
Yonsei University College of Medicine
A new 3G EGFR TKI, lazertinib: It¡¯s audacious journey from bench to clinic
|
|
Satellite Symposium 4 (Pfizer)
6/17(Thu) 12:50-13:20
|
Kyung-Hun Lee |
CV
|
Seoul National University College of Medicine
Overview of CDK4/6 inhibitors: From past to future
|
|
Satellite Symposium 5 (MSD)
6/17(Thu) 12:50-13:20
|
Chan Kim |
CV
|
CHA University School of Medicine
Optimal combination therapy with pembrolizumab and TKI for mRCC
|
|
Satellite Symposium 6 (Sanofi)
6/17(Thu) 12:50-13:20
|
Hong Jae Chon |
CV
|
CHA University School of Medicine
Current practice and new approaches with oxaliplatin in GI cancers
|
|
Satellite Symposium 7 (Lilly)
6/18(Fri) 12:50-13:10
|
Hye Sook Han |
CV
|
Chungbuk National University College of Medicine
Real-world outcomes of ramucirumab plus paclitaxel in patients with advanced gastric cancer
|
|
Satellite Symposium 8 (JEIL)
6/18(Fri) 12:50-13:10
|
Seung-Hoon Beom |
CV
|
Yonsei University College of Medicine
TAS-102, for better treatment outcomes in metastatic colorectal cancer
|
|
Satellite Symposium 9 (Roche)
6/18(Fri) 12:50-13:10
|
Dae Ho Lee |
CV
|
University of Ulsan College of Medicine
IMPower 110; I'M Powered!......Empower treatment-naive NSCLC patients?
|
|
top